| Emmaus Life Sciences (NASDAQ: EMMA) Reports Sharply Improved Q2 Results |
| |
|
Emmaus Life Sciences (NASDAQ: EMMA), a leader in sickle cell disease treatment, reported significantly improved financial results at its principal operating subsidiary, EMI Holdings, for the second quarter ended June 30, 2019. Net revenues of EMI for the 2019 second quarter increased 128% to $5.9 million, up from $2.6 million for the same period last year, and 11% from the first quarter of 2019. The increase was driven by the continuing roll-out and market acceptance of Endari®, the first treatment approved by the FDA for sickle cell disease in nearly 20 years.
Why It Matters: Sickle cell disease is an inherited blood disorder characterized by the production of an altered form of hemoglobin which polymerizes and becomes fibrous, causing red blood cells to become rigid and change form so that they appear sickle shaped instead of soft and rounded. Patients with sickle cell disease suffer from debilitating episodes of sickle cell crises, which occur when the rigid, adhesive and inflexible red blood cells occlude blood vessels. Sickle cell crises cause excruciating pain as a result of insufficient oxygen being delivered to tissue, referred to as tissue ischemia, and inflammation. These events may lead to organ damage, stroke, pulmonary complications, skin ulceration, infection and a variety of other adverse outcomes. Sickle cell disease is a significant unmet medical need, affecting approximately one hundred thousand patients in the U.S. and millions worldwide, the majority of which are of African descent. An estimated 1-in-365 African-American children are born with sickle cell disease.
What’s Next: EMMA received clearance on its investigational new drug application from the Food and Drug Administration (FDA) for the study of a new L-glutamine treatment for patients suffering from diverticulosis. EMI commenced a pilot/phase 1 study of the safety and efficacy of its treatment at multiple study sites, with patents approved in the United States, the EU, China, Russia, Japan, South Korea, Mexico, Australia and Indonesia. Emmaus has patents pending related to diverticulosis treatment in Brazil and India. The company also commenced a clinical study to determine the efficacy of the company's pharmaceutical-grade L-glutamine in lowering blood sugar in patients with type II diabetes.
|
|
| |
|
| Nemaura Medical (NASDAQ: NMRD) Reports Q1 Results |
| |
|
Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on the commercialization of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, reported financial results for the first quarter ended June 30, 2019.
Key Highlights:
• Nemaura announced an $8 Million Debt Facility provided by existing, long-term investors.
• The credit facility is at 8% interest, with interest payments due quarterly and principal due in full at maturity in five years. The credit facility has no stock, warrants, or equity related instruments, or other associated expenses.
• With adequate cash on hand and the credit facility, along with anticipated revenue, Management has instructed Maxim to suspend all ATM activities.
• Nemaura announced the first shipments of SugarBEAT® CGM devices to diabetic and pre-diabetic patients as part of its first phase of commercial launch.
• Initial demand for SugarBEAT® is exceeding Management’s expectations with nearly 20,000 expressions of interest from diabetic and pre-diabetic patients.
• Nemaura’s commercial rollout program for SugarBEAT® follows its recent CE mark approval in Europe.
• Management intends to provide shareholders with regular updates regarding commercialization progress.
• Nemaura appointed Chris Avery as Vice President of Global Business Operations to support the global commercial launch of SugarBEAT®.
Key Quote: “We have bolstered our financial position to better support the commercial launch of SugarBEAT®, which is underway, and we completed our FDA 510(k) submission. I personally want to thank each of our shareholders as they have patiently stood by our Company through our development cycle and our very recent transition to initiation of commercial sales. Given our cash position, our credit line, expected revenue, and the significant potential value of our business, we believe we are in our strongest financial position to date, and have voluntarily suspended the ATM with Maxim.” – Dr. Faz Chowdhurry, CEO
Disclosure
Nemaura Medical (NASDAQ: NMRD) is a client of RedChip Companies. NMRD agreed to pay RedChip a monthly cash fee for investor awareness services.
|
|
| |
|
| cbdMD (NYSE American: YCBD) to Host Conference Call to Discuss Q3 Results |
| |
|
cbdMD (NYSE American: YCBD), a nationally recognized consumer cannabidiol (CBD) brand, will host a conference call at 4:15 p.m., Eastern Time, on Wednesday, August 14, 2019, to discuss the company’s third quarter of fiscal year 2019 financial results and business progress.
Call Details:
Wednesday, August 14, 2019, 4:15 p.m. Eastern Time
Domestic: 1-844-407-9500
International: 1-862-298-0850
Replay dial in – Available through September 14, 2019
Domestic: 1-877-481-4010
International: 1-919-882-2331
Replay ID: 53043
The Backstory: cbdMD products are now on the shelves of more than 2,100 retailers in the US. The company reported $5.7 million in net sales for the quarter ended March 31, 2019, up 84% year-over-year and up 55% sequentially from the December 31 quarter.
Disclosure
cbdMD (NYSE American: YCBD) is a client of RedChip Companies. YCBD agreed to pay RedChip a monthly cash fee of between $5,000 and $15,000, and 5,000 shares of Rule 144 stock for RedChip investor awareness services. Additionally, the CEO of RedChip Companies owns 13,500 shares of YCBD.
|
|
| |
|
| Piedmont Lithium (NASDAQ: PLL): Updated Scoping Study Extends Project Life and Enhances Exceptional Economics |
| |
|
Piedmont Lithium (NASDAQ: PLL) reported the results of its updated Scoping Study for its vertically integrated lithium hydroxide chemical project located in North Carolina, USA. The Scoping Study includes a steady-state 22,700 tonnes per year (“t/y”) lithium hydroxide (“LiOH”) Chemical Plant supported by a Mine/Concentrator producing 160,000t/y of 6% Li2O spodumene concentrate. By-products quartz, feldspar, and mica will provide credits to the cost of lithium production.
Why It Matters: This updated Scoping Study incorporates the expanded Mineral Resource update published in June 2019 which has extended the overall project life to 25 years. The Scoping Study features:
• Integrated project to produce 22,700t/y of LiOH
• 25-year project life with 2 years of concentrate-only sales and 23 years of integrated operations
• More than 100% increase in life-of-project LiOH production compared with prior studies
• 1st quartile operating costs
• Lithium hydroxide cash costs of US$3,105/t (AISC of US$3,565/t)
• Spodumene concentrate cash costs of US$199/t (AISC of US$238/t)
• Exceptional project economics
• NPV8% of US$1.45B
• After-tax IRR of 34%
• Steady-state annual average EBITDA of US$298M
• Mine/Concentrator engineering and metallurgical testwork completed to PFS-level
• Conventional technology selection in all project aspects
Key Quote: “We are very pleased with the results of the updated Scoping Study, which reflect the benefits of a 25-year mine life, a refined concentrator flow sheet and PFS-level engineering and metallurgy. The economic benefit of developing an integrated lithium chemical business in North Carolina, USA is clear, driven by the exceptional infrastructure and human resource advantages of our location, as well as the competitive royalty and tax regime offered in the United States.” – Keith Phillips, President & CEO
Disclosure
Piedmont Lithium (NASDAQ: PLL) is a client of RedChip Companies, Inc. PLL agreed to pay RedChip Companies, Inc. a monthly cash fee for six (6) months of RedChip investor awareness services
|
|
| |
|
| Digital Ally (NASDAQ: DGLY) to Discuss Q2 Operating Results on Thursday, August 15 Conference Call |
| |
|
Digital Ally (NASDAQ: DGLY), which develops, manufactures and markets advanced digital technology products for law enforcement, homeland security and commercial security applications, will host an investor conference call on Thursday, August 15 at 11:15 a.m. EDT to discuss its operating results for the second quarter ended June 30, 2019 and the status of its patent infringement litigation against Axon Enterprise, Inc. ("Axon," formerly known as TASER International, Inc.) and other topics of interest. The Company will release its operating results for the second quarter of 2019 prior to the conference call.
Call Details: Shareholders and other interested parties may participate in the conference call by dialing (844) 761-0863 and entering conference ID #1990286 a few minutes before 11:15 a.m. EDT on Thursday, August 15, 2019.
A replay of the conference call will be available two hours after its completion, from August 15, 2019 until 11:59 p.m. EDT on October 15, 2019 by dialing 855-859-2056 and entering the conference ID #1990286.
Disclosure
Digital Ally, Inc. (NASDAQ: DGLY) is a client of RedChip Companies, Inc. DGLY agreed to pay RedChip Companies, Inc., a monthly cash fee for four (4) months of RedChip investor awareness services.
|
|
| |
|
| SinglePoint (OTCQB: SING) Becomes Master Distributor for Pure Hemp Cigarettes |
| |
|
SinglePoint (OTCQB: SING) signed a master distribution agreement with Pure Products LLC to become the primary sales and marketing solution for the company’s line of “Pure Hemp” cigarettes.
Why It Matters: The distribution agreement is a natural fit for SinglePoint CEO Greg Lambrecht as previously he led Premium Cigars International to an IPO NASDAQ listing. The company distributed and serviced over 30,000 accounts throughout North America.
Key Quote: “We are excited for this opportunity. I have many contacts still in the business from my prior distribution company and look forward to bringing Pure’s hemp cigarettes to market. There is a massive opportunity and we have been seeing retailers looking for this type of product during our due diligence into the space.” – Greg Lambrecht, CEO
Disclosure
SinglePoint, Inc. (OTCQB: SING) is a client of RedChip Companies, Inc. SING agreed to pay RedChip Companies, Inc. a monthly cash fee for RedChip investor awareness services and consulting services
|
|
| |
|
| Immuron (NASDAQ: IMRN) Reports Results in Severe Alcoholic Hepatitis Clinical Trial |
| |
|
Immuron Ltd. (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of gut mediated diseases, announced topline results of the clinical study conducted by the TREAT Consortium, which was funded by the National Institute of Alcohol Abuse and Alcoholism (NIAAA).
Why It Matters: The primary objective of the TREAT-003 study was to evaluate the safety and efficacy of IMM-124E at two oral dosage levels as compared with a placebo and provide proof of concept in human subjects for the Mechanism of Action (MoA) in patients with severe alcoholic hepatitis being treated with steroids. No Suspected Unexpected Serious Adverse Reactions (SUSAR) were reported and no differences in Serious Adverse Events (SAE) were observed across the three arms of the study and no SAE was considered related to the study drug by investigators. These data indicate that IMM-124E is safe to use in patients with severe alcoholic hepatitis but does not reduce circulating lipopolysaccharide levels, mortality or have an impact on MELD score in the study population.
Key Quote: “The IMM-124E drug candidate has been developed to target LPS in the gut and prevent it translocating into the portal circulation and the major objective was to determine if orally administered IMM-124E could reduce endotoxemia in patients with severe alcoholic hepatitis being treated with steroids. In this extreme clinical setting in patients with established severe disease and very high endotoxin load, the study results demonstrated that during the 28-day treatment period there was no statistically significant reduction of serum endotoxin levels or markers of liver injury in the treatment groups when compared to placebo. The possibility of using IMM-124E prior to development of severe disease and its ability to reduce endotoxin load in that setting remains unexplored. This is a disease with a high mortality rate, nine patients enrolled in the study died due to complications associated with the disease. There remains an urgent medical need for new treatments.” – Gary Jacob, CEO
Disclosure
Immuron Ltd. (NASDAQ: IMRN) is a client of RedChip Companies, Inc. IMRN agreed to pay RedChip Companies, Inc. a monthly cash fee for (3) months of investor awareness services.
|
|
| |
|
| Medalist Diversified REIT (NASDAQ: MDRR) to Host Investor Webinar on August 13 |
| |
|
Medalist Diversified REIT (NASDAQ: MDRR), a Virginia-based real estate investment trust that specializes in acquiring, owning and managing value-add commercial real estate in the Southeast region of the U.S., announced that it will participate in an investor webinar and Q&A session on Tuesday, August 13, 2019, at 11:00 a.m. ET, hosted by RedChip Companies.
The webinar will feature a presentation by Chairman & CEO Tim Messier, who will discuss the company’s track record, current effective approximate dividend yield of 16.2%, and future growth plans.
To register for the free webinar, please visit: MDRR Webinar Registration
The Backstory: MDRR’s strategy is to focus on value-add and opportunistic commercial real estate which is expected to provide an attractive balance of risk and returns. Medalist utilizes a rigorous, consistent and replicable process for sourcing and conducting due diligence of acquisitions. The Company seeks to maximize operating performance of current properties by utilizing a hands-on approach to property management while monitoring the middle market real estate markets in the Southeast for acquisition opportunities and disposal of properties as considered appropriate.
Disclosure
Medalist Diversified REIT (MDRR) is a client of RedChip Companies, Inc. MDRR agreed to pay RedChip Companies, Inc. a monthly cash fee for four (4) months of RedChip investor awareness services.
|
|
| |
|
| Catasys (NASDAQ: CATS) to Host Q2 Earnings Call on Wednesday, August 14 |
| |
|
Catasys (NASDAQ: CATS), a leading AI and technology-enabled healthcare company, announced that the Company will be releasing financial results for its second quarter ended June 30, 2019, after the closing of the stock market on Wednesday, August 14, 2019. The Company will also host a conference call/webcast that same day at 4:30 pm ET/1:30 pm PT.
Call Details: 877-705-2969 (domestic) or 201-689-8868 (international)
Webcast
78449.themediaframe.com/dataconf/productusers /cats/mediaframe/31789/indexl.html
Those who are unable to attend the conference call live can use the following information to hear a replay version:
Conference ID#: 13672721
Conference Call Replay: 877-660-6853 (domestic) or 201-612-7415 (international)
Expiration Date: 8/21/2019
The Backstory: Catasys harnesses proprietary big data predictive analytics, artificial intelligence and telehealth, combined with human interaction, to deliver improved member health and validated outcomes and savings to health plans. Our mission is to help improve the health and save the lives of as many people as possible.
Catasys' integrated, technology-enabled OnTrak solution--contracted with a growing number of national and regional health plans--is designed to treat members with behavioral conditions that cause or exacerbate co-existing medical conditions such as diabetes, hypertension, coronary artery disease, COPD, and congestive heart failure, which result in high medical costs.
Catasys has a unique ability to engage these members, who do not otherwise seek behavioral healthcare, leveraging proprietary enrollment capabilities built on deep insights into the drivers of care avoidance.
OnTrak integrates evidence-based psychosocial and medical interventions delivered either in-person or via telehealth, along with care coaching and in-market Community Care Coordinators who address the social determinants of health, including loneliness. The program improves member health and delivers validated cost savings to healthcare payers of more than 50 percent for enrolled members. OnTrak is available to members of several leading health plans in Alabama, California, Connecticut, Florida, Georgia, Illinois, Iowa, Kansas, Kentucky, Louisiana, Massachusetts, Mississippi, Missouri, Nebraska, New Jersey, North Carolina, Oklahoma, Pennsylvania, South Carolina, Tennessee, Texas, Virginia, West Virginia and Wisconsin.
Disclosure
Catasys (NASDAQ: CATS) is a client of RedChip Companies, Inc. CATS agreed to pay RedChip Companies, Inc. a monthly cash fee for RedChip investor awareness services and consulting services.
|
|
| |
|
| ChineseInvestors.com (OTCQB: CIIX) Appoints Shelby Chan as its Newest Independent Director |
| |
|
ChineseInvestors.com (OTCQB: CIIX), a premier provider of financial news and education for the Chinese-speaking community, announced that its Board of Directors has appointed Shelby Chan as an Independent Director, effective August 1, 2019, completing the Company's Board as its fifth member.
Why It Matters: Ms. Chan, a licensed CPA in Hong Kong, has experience in financial reporting and listing compliance. She has worked in audit firms and with Hong Kong listed companies including Wen Holdings Limited, where she was a finance manager, and Mazars CPA where she held the position of Senior Auditor. Currently, Ms. Chan is a Senior Accounts Manager with Four Seas Mercantile Holdings Limited (HKEx:374). Ms. Chan received her Bachelor of Business Administration (Accounting & Finance) at the University of Hong Kong in 2007.
Key Quote: “We are pleased to welcome Ms. Chan to ChineseInvestors.com, Inc's Board of Directors. Her financial experience and her public company experience will be an asset to the Company.” – Warren Wang, CEO
The Backstory: Founded in 1999, ChineseInvestors.com endeavors to be an innovative company providing: (a) real-time market commentary, analysis and educational-related services in Chinese language character sets (traditional and simplified); (b) advertising and public relations-related support services; and (c) sales of industrial hemp products and other health and wellness products.
Disclosure
ChineseInvestors.com, Inc. (OTCQB: CIIX) is a client of RedChip Companies. CIIX pays RedChip a monthly cash fee for twelve (12) months of investor awareness services.
|
|
| |
|
| |
| Quote of the Week |
| |
"Do your homework, understand companies you invest in forwards and backwards."
- Charles Diker, Diker Management-Microcap Superstar |
|
|
|
|
|
|
|
| About RedChip |
| |
| RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on small-cap and mid-cap companies. Since 1992, RedChip has delivered concrete, measurable results for its clients through the most comprehensive service platform in the industry for small-cap and mid-cap companies. These services include a worldwide distribution network for its stock research written by analysts holding the CFA designation; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated over 2.3 million unique investor views; quarterly global online institutional and retail investor conferences that reach over 10,000 investors annually; "The RedChip Money Report" television show which airs in 100 million homes across the U.S. on The Family Channel; a weekly newsletter delivered to 60,000 investors; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more. |
| |
| RedChip Disclosure |
| |
RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
RedChip Visibility is a division of RedChip Companies, Inc. and offers research services to paying clients. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that the RedChip Companies Inc. is an investor relations firm hired by certain Companies to increase investor awareness to the small-cap equity community.
Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov and view RedChip’s Disclosures. |
|
| |
|
|
| |
|
|
Copyright © 2019 RedChip Companies, Inc. All Rights Reserved.
You are receiving this message because this email address has signed up to receive News Alerts.
|
|
|
|
|
| | |
